This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barrios, A.
Right arrow Articles by Soriano, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barrios, A.
Right arrow Articles by Soriano, V.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, September 2003, p. 4421-4423, Vol. 41, No. 9
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.9.4421-4423.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Role of Baseline Human Immunodeficiency Virus Genotype as a Predictor of Viral Response to Tenofovir in Heavily Pretreated Patients

Ana Barrios,1 Carmen de Mendoza,1 Luz Martín-Carbonero,1 Esteve Ribera,2 Pere Domingo,3 María José Galindo,4 Juan Gálvez,5 Vicente Estrada,6 David Dalmau,7 Víctor Asensi,8 and Vincent Soriano1*

Service of Infectious Diseases, Instituto de Salud Carlos III,1 HIV Unit, Hospital Clínico San Carlos, Madrid,6 HIV Unit, Hospital Vall D'Hebron,2 Infectious Diseases Unit, Hospital de Sant Pau,3 HIV Unit, Mutua de Terrassa, Barcelona,7 HIV Unit, Hospital Clínico, Valencia,4 HIV Unit, Hospital Virgen Macarena, Seville,5 HIV Unit, Hospital Central de Asturias, Oviedo, Spain8

Received 13 January 2003/ Returned for modification 23 March 2003/ Accepted 23 June 2003

Human immunodeficiency virus (HIV)-infected patients (n = 153) failing antiretroviral therapy after exposure to compounds from all three drug families were monitored for 6 months after beginning a rescue intervention program including tenofovir (TDF). At 3 months, levels of HIV RNA in plasma dropped by a mean of 0.9 log10 and the mean CD4 count increased by 52 cells/µl. At 6 months, HIV RNA levels had dropped by a mean of 1.06 log10 and the mean CD4 count had increased by 49 cells/µl. Only five (3.7%) patients discontinued TDF use due to adverse events. In the multivariate analysis, the presence of M41L and/or L210W at baseline was the only viral determinant of a lower response to TDF.

* Corresponding author. Mailing address: Calle Nueva Zelanda 54, 4° B, 28035 Madrid, Spain. Phone: 34 91 4532500. Fax: 34 91 7336614. E-mail: vsoriano{at}dragonet.es.

Journal of Clinical Microbiology, September 2003, p. 4421-4423, Vol. 41, No. 9
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.9.4421-4423.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»